First-quarter acquisition activity lifts hopes for a big year
After a slow 2017, first-quarter biopharma acquisition activity could signal a turnaround.
Biotech gets creative about the pay cheque
Amid a backlash over the high prices of advanced therapies, biotech companies are coming up with new payment models.
Blockbuster approvals line up for biopharma in 2018
2018 shaping up to be a bumper approval year, as Juno Therapeutics, Epizyme and Avexis line up to launch potential blockbusters.